Feverfew CO2 Extract (MIG-99) for Migraine Prevention
Symptoms Studied
Recurrent migraine attacks with or without aura, occurring multiple times per month. Throbbing headache, often unilateral, with nausea and sensitivity to light and sound.
Research Hypothesis
Feverfew's parthenolide content inhibits platelet aggregation and serotonin release, and may reduce inflammatory mediators involved in migraine pathogenesis.
Intervention Tested
Feverfew (Tanacetum parthenium) Extract
6.25mg feverfew CO2 extract (MIG-99) three times daily, standardized to parthenolide content
Study Results
Before Treatment
Adults with migraine (IHS criteria) experiencing at least 2 attacks per month, not on other migraine prophylaxis.
After Treatment
Migraine frequency decreased by 1.9 attacks/month with MIG-99 vs 1.3 with placebo (p=0.0456). Responder rate odds ratio 3.4 in favor of feverfew (p=0.0049).
Timeline to Improvement
Gradual improvement over 4-16 weeks of consistent use
Side Effects
Mouth ulceration possible. GI discomfort in some patients. Post-feverfew syndrome (rebound headaches) reported if stopped abruptly after long-term use.
Source
- Feverfew CO2 Extract (MIG-99) for Migraine Prevention
Diener HC, et al. Cephalalgia. 2005;25(11):1031-1041
Conclusion
Feverfew may provide modest benefit for migraine prevention, though evidence is mixed. Most appropriate as an option for those preferring herbal approaches.
Did this work for you?
Share your experience
Sign in to voteTry It Yourself
Create your own trial based on this study and share your results.
Replicate This TrialSimilar Trials
More trials for Migraines coming soon.
Browse all Migraines trials
Comments (0)